For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Patients who received nivolumab had longer DFS than those who received standard care. OS will be evaluated after a prespecified number of deaths occur. The addition of adjuvant nivolumab to ...

Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC ...

(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...